F. Hoffmann-La Roche Ltd. has discovered benzothiazolyl bicyclo[1.1.1]pentane derivatives acting as hepatitis B virus (HBV) HBeAg and HBsAg secretion inhibitors, reported to be useful for the treatment of HBV infections.